Clinical Trials in La Roche-sur-Yon, France

1 recruiting

Showing 120 of 23 trials

Recruiting
Phase 2

Phase II Efficacy Study of Repotrectinib in Frail and/or Elderly Patients With ROS1-rearranged Advanced NSCLC

NSCLC Stage IV
Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer30 enrolled20 locationsNCT06552234
Recruiting
Phase 3

Chemotherapy De-escalation in HR +, HER2-, Intermediate-risk Early Breast Cancer Treated With Adjuvant Ribociclib

Breast Cancer
UNICANCER3,902 enrolled70 locationsNCT07237256
Recruiting
Phase 3

Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]

Non-small Cell Lung CancerNSCLC
Merck Sharp & Dohme LLC851 enrolled204 locationsNCT06422143
Recruiting
Phase 3

Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor

OSE Immunotherapeutics363 enrolled207 locationsNCT06472245
Recruiting
Phase 3

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

Breast Cancer
Stemline Therapeutics, Inc.4,220 enrolled524 locationsNCT06492616
Recruiting
Phase 3

Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease

Breast Cancer
Pfizer1,020 enrolled518 locationsNCT06760637
Recruiting
Phase 3

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

Amgen750 enrolled379 locationsNCT05920356
Recruiting
Not Applicable

Study Evaluating DNA Double-strand Breaks (DSBs) REpair Factors (POLQ, Shieldin Complex and 53BP1) Expression as Biomarker of PARP Inhibitor Resistance in Patients With Deleterious Germline Mutation in BRCA 1/2 and HER2-negative, Metastatic or Locally Advanced Breast Cancer.

Breast Cancer
Institut Claudius Regaud120 enrolled25 locationsNCT05378204
Recruiting
Phase 3

A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer

Breast Cancer
AstraZeneca100 enrolled40 locationsNCT07205822
Recruiting
Not Applicable

Streamlined Geriatric and Oncological Evaluation Based On IC Technology

Breast CancerLung CancerComorbidities and Coexisting Conditions
Institut Bergonié720 enrolled10 locationsNCT05720910
Recruiting
Phase 2

A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Prostate Cancer
Astellas Pharma Global Development, Inc.900 enrolled241 locationsNCT02960022
Recruiting
Phase 3

Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated

Intergroupe Francophone de Cancerologie Thoracique133 enrolled29 locationsNCT06908993
Recruiting
Phase 4

PROspective Master-protocol for Evaluation of Systemic THErapeutics in Elderly With Thoracic Malignancies

GFPC Investigation500 enrolled41 locationsNCT06646471
Recruiting

Long-Terms Responders in Metastatic Lung Cancer: Better Understanding for Better Management (Lungevity Study)

Metastatic Lung CancerMetastatic NSCLCMetastatic Small Cell Lung Cancer
GFPC Investigation1,000 enrolled46 locationsNCT07243132
Recruiting
Phase 2

Capecitabine Plus Pembrolizumab in Patients With Triple Negative Breast Cancer After Chemo-immunotherapy and Surgery

Triple Negative Breast Neoplasms
UNICANCER220 enrolled20 locationsNCT05973864
Recruiting
Not Applicable

Analysis of Biological Characteristics of Advanced ALK-rearranged NSCLC

Non-small Cell Lung CancerALK Gene Rearrangement Positive
Groupe Francais De Pneumo-Cancerologie100 enrolled46 locationsNCT05122806
Recruiting
Phase 2

Trial for Local Ablative Treatment (LAT) Optimization in Patients With Advanced Non-Small Cells Lung Cancer (NSCLC) Presenting an Anaplastic Lymphoma Kinase (ALK) Rearrangement Treated by Brigatinib

NSCLC
Groupe Francais De Pneumo-Cancerologie45 enrolled27 locationsNCT06620835
Recruiting
Not Applicable

Program of Physical Activity, Nutrition and Supportive to Improve the Quality of Life of Breast Cancer Survivors

Breast CancerQuality of Life
Siel Bleu160 enrolled8 locationsNCT05658341
Recruiting
Phase 3

Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO

Head and Neck CancerRenal Cell CarcinomaLung Cancer Metastatic
UNICANCER646 enrolled40 locationsNCT05078047
Recruiting
Phase 2Phase 3

De-escalation Immunotherapy mAintenance Duration Trial for Stage IV Lung Cancer Patients With Disease Control After Chemo-immunotherapy Induction

Metastatic NSCLC
Intergroupe Francophone de Cancerologie Thoracique1,360 enrolled44 locationsNCT05255302